Boan’s site-specific Integration Cell Line Development Platform BA-Fastcell® Debuted at BPI Asia 2024

Asia's premier biomanufacturing summit,BioProcess International Asia 2024（BPI Asia 2024）,was held in Koyto, Japan from Oct.21-23. Dr. Changlin Dou, the R&D President and Chief Operating Offi...

Boan Reports Positive PK Similarity Study Results of BA1104

The Results of Phase I Pharmacokinetic Similarity Study of Boan Biotech’s Nivolumab Published in Journal of BioDrugsThe phase I clinical study aimed to establish the pharmacokinetic (PK) similar...

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2024

INTERIM REPORT 2024

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024

Articles of Association

Boan Biotech Announces 2024 Half Year Results: Revenue Grows by 39%, Net Profit Increases by RMB 180 Million

YANTAI, China, Aug. 27, 2024-- Boan Biotech (6955.HK) today announced its 2024 half-year results and latest developments.During the reporting period, the company's total revenue was RMB 363 millio...

ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2024

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

Notice of Board Meeting